Hemophilia A Treatment Market Analysis by Patient (Pediatric, and Adult); by Treatment (Prophylaxis, and On-demand); by Therapy (Factor Replacement Therapy, and Non-Factor Replacement Therapy); by Drug Class (Vasopressin, and Coagulation Factor); and by Route of Administration (Injectable and Nasal Spray)-Global Supply & Demand Analysis & Opportunity Outlook 2023-2033

  • Product Code:
  • Published Date:
    30 Oct 2022
  • Region:
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:

Impact Analysis on the Growth of Market

Inflation and Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.



The Research Report is Updated with 2022 Base Year, 2023 Estimated year and Forecast till 2035 with Market Insights.

With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2022 as base year, 2023 as estimated year and forecast to 2035. This will have market drivers, recovery rate in the market, insights and competitive analysis.

Market Overview:

Translate Report

Global Hemophilia A Treatment Market Scope Report


Base Year


Forecast Year




Base Year Market Size (2022)

 ~ USD 13 Billion

Forecast Year Market Size (2033)

~ USD 27 Billion

Global Hemophilia A Treatment Market Size, Forecast, and Trend Highlights Over 2023 - 2033

The global hemophilia A treatment market is estimated to garner a revenue of ~ USD 27 billion by the end of 2033 by growing at a CAGR of ~8% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~ USD 13 billion in the year 2022. The prevalence of hemophilia A is the primary factor driving the growth of the global hemophilia A treatment market. For instance, it is estimated that there are about 1 in ~5001 male births of cases of Hemophilia A in the United States (U.S.) each year.





Hemophilia A, also known as classic hemophilia, is caused by the deficiency of the protein factor VIII, which helps blood clot. It also leads to excessive internal and external bleeding after any damage or injury. Hemophilia is generally treated by injecting a clotting factor or plasma.

Global Hemophilia A Treatment Market: Growth Drivers and Challenges

Growth Drivers

  • Occurrence of Hemophilia A During Birth – It is estimated that only in the U. S. there are ~401 babies born with hemophilia A every year. Most people with the disease have inherited hemophilia, in which the disease is inherited from the parent to the child. Such children should suffer from a nearly absolute lack of clotting factor, making them prone to internal injuries, which leads to life-threatening damage to organs or tissues. Most babies are tested for hemophilia either through a parental genetic test before birth or a special blood test after birth.  

  • Enough Access to Specialized Care for Hemophilia – It has been observed that over 69% of people with hemophilia in the U.S. have access to comprehensive and multidisciplinary care from hemophilia treatment centers (HTC)s, funded by the federal government.

  • Enough Access to Lab tests – It is believed that there is more than 24,800 business in diagnostic & medical laboratories in the U.S., as of 2022.

  • Prospective Use of Gene Therapy for Treatment – In 2022, gene therapy was observed to have brought down the annualized bleeding rates in hemophilia patients by ~91%.


  • High Costs Involved in the Treatment

  • Limited Screening Tests for Hemophilia in Poor Economies

  • Lack of Awareness among People about Hemophilia and Its Treatments

The global hemophilia A treatment market is segmented and analyzed for demand and supply by treatment into prophylaxis and on-demand. Between these, the prophylaxis segment is anticipated to hold the largest market size by the end of 2033. The segmental growth is mostly inspired by the growing preference for the treatment method among adult patients to prevent bleeding as a result of hemophilia. Prophylaxis was observed to reduce the risk of intracranial bleeding by over 49% in patients with hemophilia.

Global Hemophilia A Treatment Market Regional Synopsis

Regionally, the global hemophilia A treatment market is studied into five major regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. Amongst these markets, the market in the Asia Pacific region is projected to hold a significant share by the end of 2033. The increasing occurrence of hemophilia among the population in the region is the primary factor driving the regional market growth. For instance, in 2021, more than 1 lakh people were observed to be suffering from hemophilia.

Market Segmentation

Our in-depth analysis of the global hemophilia a treatment market includes the following segments:

By Patient

  • Pediatric

  • Adult

By Treatment

  • Prophylaxis

  • On Demand

By Therapy

  • Factor Replacement Therapy

  • Non-factor Replacement Therapy

By Drug Class

  • Vasopressin

  • Coagulation Factor

By Route of Administration

  • Injectable

  • Nasal Spray

Customize this Report: Request Customization

Key Companies Dominating the Global Hemophilia A Treatment Market

Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global hemophilia A treatment market that are included in our report are Biotest AG, Pfizer Inc., CSL Behring LLC, BIOGEN INC., Kedrion S.p.A, Ferring International Center S.A., Genentech, Inc., Novo Nordisk Inc., Octapharma AG, Bayer AG, and others.

Global Hemophilia A Treatment Market: Latest Developments

  • September, 2022: Pfizer Inc. announced in collaboration with Sangamo Therapeutics, the reopening of recruitment for the phase 3 trial for the investigational gene therapy, giroctocogene fitelparvovec to treat moderately severe to severe hemophilia A.

  • March, 2019: Biotest AG announced receiving approval for the double concentrated Haemoctin(R) SDH for better treatment of hemophilia A in Europe.

Key Reasons to Buy Our Report

  • The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.

  • It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.

  • The report includes detailed company profiles of the major players dominating the market.

  • We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.

  • We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.

Geography Analysis:

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

  • North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook



Please enter your personal details below
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
  1. Biotest AG
  2. Pfizer Inc.
  3. CSL Behring LLC
  5. Kedrion S.p.A
  6. Ferring International Center S.A.
  7. Genentech, Inc.
  8. Novo Nordisk Inc.
  9. Octapharma AG
  10. Bayer AG
Please enter your personal details below
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports